New Value Capital
VC Fund
Shenzhen, China
New Value Capital is a private equity investment fund management company. It is a private equity fund with fund management, investment management, and investment consulting as its main business as an Investment fund management agency. The company's investment direction is biomedicine, advanced manufacturing, Artificial Intelligence, and TMTindustries with an investment focus on projects in the initial stage, growth period, mature stage, and Pre-IPO stage.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries New Value Capital invests in
Stages New Value Capital invests in
Countries New Value Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $425k–$41M
- Series B
- $14M–$31M
Investment Focus
Industry
- Biotechnology 3 (21%)
- Manufacturing 3 (21%)
- Semiconductor 3 (21%)
- Pharmaceutical 3 (21%)
- Medical 2 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Junxin Jia
Chariman and President
|
Chariman and President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ATAPEX
|
ATAPEX aims to break the domestic mass production gap of ultra-precision metal sheet processing. Its product business covers Display panel, display terminal, VR/AR display, including Divide Open Mask for AMOLED, Divide Fine Metal Mask, Micro OLED Open Mask for silicon-based OLED, metal support sheet for display terminal and other high-endultra-fine processing products, connected in series A related industry chain to help customers solve various problems such as less choice of related products, unstable quality, long delivery time etc. | $28.1M / Series B / Jan 04, 2024 | |
Shuwei
|
Shuwei is an indoor positioning services provider for mobile Internet platforms and smartphone manufacturers.Its technology is applied to shopping malls, train stations, office buildings, and restaurants. Shuwei also launched an open precision marketing platform that offers relevant content related to the vehicle, as well as information aboutsimilar cars.The Shenzhen, Guangdon-based company was established in 2014. | $14M / Series D / Dec 20, 2023 | |
Sinsegye
|
Sinsegye operates as a product-driven enterprise company. Sinsegye is an industrial control supercomputing infrastructure supplier. | $41M / Series A / Oct 30, 2023 | |
AlphaMol
|
AlphaMol is a biopharmaceutical company that aims to discover and develop new drug molecules to treat human disorders and diseases. It mainly focuses on G protein-coupled receptor (GPCR)-related signaling pathways. | Series A / Aug 24, 2023 | |
Wuxi Xinxiang
|
Wuxi Xinxiang is an Integrated control solution service provide company. | Series B / Jun 08, 2023 | |
Camsense
|
Camsense focuses on R&D and manufacturing of vision space positioning technology. It provides customers with highly precise sensors with its self-developed core algorithm and chips. Its products can be applied in consumer robots, industrial test, and surgeries. | $12.9M / Series C / Sep 16, 2022 | |
Huatai Semiconductor
|
Huatai Semiconductor is an analog and mixed-signal chip design service provider, focusing on analog/mixed-signal chip design. | $13.3M / Series A / Jul 29, 2022 | |
Synceres Biosciences
|
Sunrise is a full-chain synthetic biology research and development platform. | $15.7M / Series A / Mar 16, 2022 | |
|
QureBio
|
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug developmentincluding phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform.The company was founded in 2017 and is based in Pudong District, Shanghai. | $31.3M / Series B / Dec 24, 2021 | |
Zenitar
|
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia. | $16.8M / Series A / Dec 08, 2021 | |
| See all 14 investments → | |||
Co-Investors
Bojiang Capital
2 deals together
Shenzhen Capital Group
2 deals together
BOCOM International
1 deal together
CASVC
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does New Value Capital invest in?
New Value Capital invests primarily in Biotechnology, Manufacturing and Semiconductor startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is New Value Capital's check size?
New Value Capital typically joins rounds of $425k–$41M at Series A and $14M–$31M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds New Value Capital participates in.
How do I contact New Value Capital?
Public channels for New Value Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at New Value Capital?
The team at New Value Capital includes Junxin Jia (Chariman and President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
